Timothy Sangiovanni Biography and Net Worth

Senior Vice President, Corporate Controller of Zevra Therapeutics

Mr. Sangiovanni has served as Zevra Therapeutics (then KemPharm, Inc.) vice president, corporate controller since February 2017, having previously held the position of director, financial reporting since August 2015.

Prior to joining Zevra, Mr. Sangiovanni was the internal audit manager at Tupperware Brands Corporation, a leading publicly held marketer of home and personal care products, audit manager at KPMG LLP, a global network of professional firms providing audit, tax and advisory services, and billing analyst at Switch and Data Facilities Company, Inc. (today, Equinix, Inc.), a leading publicly held provider of global colocation data center services.

Mr. Sangiovanni is a Certified Public Accountant in the State of Florida and earned his Bachelor of Arts in accounting from the University of South Florida.

What is Timothy J. Sangiovanni's net worth?: The estimated net worth of Timothy J. Sangiovanni is at least $141.51 thousand as of February 13th, 2025. Mr. Sangiovanni owns 16,341 shares of Zevra Therapeutics stock worth more than $141,513 as of December 5th. This net worth estimate does not reflect any other investments that Mr. Sangiovanni may own. Learn More about Timothy J. Sangiovanni's net worth.
How do I contact Timothy J. Sangiovanni?: The corporate mailing address for Mr. Sangiovanni and other Zevra Therapeutics executives is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. Zevra Therapeutics can also be reached via phone at (321) 939-3416 and via email at [email protected]. Learn More on Timothy J. Sangiovanni's contact information.
Has Timothy J. Sangiovanni been buying or selling shares of Zevra Therapeutics?: Timothy J. Sangiovanni has not been actively trading shares of Zevra Therapeutics during the past quarter. Most recently, Timothy J. Sangiovanni sold 3,000 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a transaction totalling $23,580.00. Following the completion of the sale, the senior vice president now directly owns 16,341 shares of the company's stock, valued at $128,440.26. Learn More on Timothy J. Sangiovanni's trading history.
Who are Zevra Therapeutics' active insiders?: Zevra Therapeutics' insider roster includes Thomas Anderson (Director), John Bode (Director), R. Clifton (Chief Financial Officer & Treasurer), Neil McFarlane (President & Chief Executive Officer), Timothy Sangiovanni (Senior Vice President, Corporate Controller), Joshua Schafer (Chief Commercial Officer), and Corey Watton (Director). Learn More on Zevra Therapeutics' active insiders.
Are insiders buying or selling shares of Zevra Therapeutics?: In the last year, Zevra Therapeutics insiders bought shares 4 times. They purchased a total of 18,475 shares worth more than $152,485.25. In the last year, insiders at the sold shares 5 times. They sold a total of 105,273 shares worth more than $885,165.78. The most recent insider tranaction occured on October, 10th when CEO Neil F Mcfarlane sold 19,500 shares worth more than $210,990.00. Insiders at Zevra Therapeutics own 2.4% of the company. Learn More about insider trades at Zevra Therapeutics.
Information on this page was last updated on 10/10/2025.

Timothy J. Sangiovanni Insider Trading History at Zevra Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/13/2025	Sell	3,000	$7.86	$23,580.00	16,341
3/10/2023	Buy	1,200	$4.14	$4,968.00	4,449

Timothy J. Sangiovanni Buying and Selling Activity at Zevra Therapeutics

Zevra Therapeutics Company Overview

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Today's Range

Now: $8.66

$8.48

$8.80

50 Day Range

MA: $9.79

$8.17

$11.78

2 Week Range

Now: $8.66

$6.19

$13.16

Volume

823,188 shs

Average Volume

1,395,027 shs

Market Capitalization

$487.56 million

P/E Ratio

18.43

Dividend Yield

N/A

Beta

1.01